Clinical-stage biopharma developing vaccines against antimicrobial-resistant bacterial infections.
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Series A Zurich-based LimmaTech Biologics raised a $37M Series A co-led by Adjuvant Capital, AXA IM Alts and Novo Holdings REPAIR Impact Fund. | $37M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.